Inflammatory Bowel Disease Drugs Market To Reach $9.3bn In 2019, A New Study Predicts

12 September 2018
Pharma
A new report by visiongain forecasts the world market for inflammatory bowel disease medicines will reach $9.3 billion in 2019. That revenue prediction and others appear in Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn’s Disease and Ulcerative Colitis. Visiongain, a business information publisher and consultancy in London, UK, published that study in January 2016.Visiongain predicts that the IBD pharmaceuticals market will grow in revenues owing to the increasing use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions at present, they dominate the market for revenue generation and held 68% of the global IBD market in 2014. From 2016 that worldwide market will be stimulated by rising disease incidence and non-invasive diagnosis, as well as technological advances in medicines. That industry’s R&D holds promise.Sandra Wenas, a senior pharmaceutical industry analyst in visiongain, said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to offset this loss.“An increased use of biologics will be the main sales driver to 2026. As more doctors advocate the top-down therapy approach, and more studies justify the cost effectiveness of monoclonal antibodies for IBD, biological drugs’ revenues will expand and claim 57% of the IBD treatment market’s revenues by 2026. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”Visiongain’s new analysis shows revenue forecasts to 2026 at overall world market, submarket, product and national level. First it forecasts five world-level submarkets:• Biologics, including monoclonal antibodies (mAbs) • Aminosalicylates • Antibiotics • Corticosteroids • Immunomodulators.That investigation next predicts the revenues of 17 leading IBD drugs to 2026, including Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri, Cimzia, Entocort and recently approved treatments Uceris, Simponi and Entyvio.Visiongain’s analysis includes trends and revenue predictions of 11 leading national markets to 2026:• US • Japan • EU5:Germany, France, UK, Spain and Italy • BRIC: Brazil, Russia, India and China.The study also discusses research and development, including agents in these classes:• Interleukin (IL) inhibitors • Cell-adhesion molecule (CAM) inhibitors • TNF-alpha inhibitors • Stem cell therapies • JAK inhibitors • Toll-like receptor agonists.That new report includes qualitative analyses and interviews with two authorities in that field. It also discusses leading companies: AbbVie, Janssen Biotech, Allergan and Shire Pharmaceuticals.Inflammatory Bowel Diseases (IBD) 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostics and contract services.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever